Exchange: NASDAQ·Updated 01:28 PM EDT
News
all
press releases
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company's disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares...
Business Wire
More News
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PR Newswire NEW YORK, Aug. 20, 2026 EyePoint...
PR Newswire
The Catalyst Explosion: Insider Buying, Phase 3 Wins, Bitcoin Billions and Shorts Under Pressure
The market is serving up a explosive mix of catalysts for listings like NeOnc Technologies Holdings (NASDAQ:NTHI), Wetour Robotics (NASDAQ:WETO), Kura Oncology (NASDAQ:KURA), Amylyx Pharmaceuticals (NASDAQ:AMLX), EyePoint Pharmaceuticals (NASDAQ:EYPT), and Super League Enterprise (NASDAQ:SLE).
24-7 Market News
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
Zacks
EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’
RBC Capital said that even if EyePoint’s second Phase 3 study delivers positive results, questions would remain over whether the U.S. Food and Drug Administration would approve the treatment based on a single trial.
Stocktwits
Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
The sell-offs followed a failed trial, a massive recall, and a CEO's exit.
Stocktwits
Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,459.78read more...
Benzinga
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.
Stocktwits
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.
Stocktwits
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
EyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.